Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) - Stock analysts at SVB Leerink lifted their Q1 2021 earnings estimates for Aurinia Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 26th. SVB Leerink analyst J. Schwartz now anticipates that the biotechnology company will earn ($0.11) per share for the quarter, up from their prior estimate of ($0.12). SVB Leerink currently has a "Outperform" rating and a $28.00 target price on the stock. SVB Leerink also issued estimates for Aurinia Pharmaceuticals' Q2 2021 earnings at $0.01 EPS, Q3 2021 earnings at $0.02 EPS, Q4 2021 earnings at $0.03 EPS and FY2021 earnings at ($0.06) EPS.
A number of other research firms have also commented on AUPH. Cantor Fitzgerald boosted their price objective on Aurinia Pharmaceuticals from $27.00 to $34.00 and gave the stock an "overweight" rating in a research note on Tuesday. HC Wainwright boosted their price target on shares of Aurinia Pharmaceuticals from $30.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday. Bloom Burton downgraded Aurinia Pharmaceuticals from a "buy" rating to an "accumulate" rating in a report on Tuesday, November 3rd. Oppenheimer lifted their price target on shares of Aurinia Pharmaceuticals from $20.00 to $28.00 in a research report on Monday. Finally, Zacks Investment Research upgraded shares of Aurinia Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Wednesday. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. The stock has a consensus rating of "Buy" and an average target price of $26.50.
NASDAQ:AUPH opened at $17.08 on Friday. Aurinia Pharmaceuticals has a 12-month low of $9.83 and a 12-month high of $20.50. The firm has a 50-day moving average price of $14.15 and a 200 day moving average price of $14.44. The firm has a market capitalization of $2.16 billion, a PE ratio of -11.62 and a beta of 0.87. Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its earnings results on Sunday, November 15th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.23) by ($0.05). Aurinia Pharmaceuticals had a negative return on equity of 36.98% and a negative net margin of 173,992.23%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.06 million.
A number of hedge funds and other institutional investors have recently modified their holdings of AUPH. Advisory Alpha LLC bought a new stake in Aurinia Pharmaceuticals during the 3rd quarter worth approximately $31,000. Lindbrook Capital LLC bought a new position in shares of Aurinia Pharmaceuticals in the 4th quarter worth $55,000. Exane Derivatives increased its stake in Aurinia Pharmaceuticals by 50.0% in the third quarter. Exane Derivatives now owns 5,100 shares of the biotechnology company's stock valued at $75,000 after acquiring an additional 1,700 shares during the last quarter. Chiron Capital Management LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 3rd quarter valued at about $143,000. Finally, Coastal Investment Advisors Inc. purchased a new stake in Aurinia Pharmaceuticals in the third quarter worth approximately $167,000. Institutional investors and hedge funds own 51.21% of the company's stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Further Reading: How to identify percentage decliners
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
7 Semiconductor Stocks Set to Gain From the Chip Shortage
Who knew that something so tiny could create such a big problem? However, that’s the case with the semiconductor industry. Chip manufacturers are facing supply chain disruptions due to the Covid-19 pandemic.
Semiconductors are in high demand for the big tech companies who need the chips to power the servers for their data centers. But they are also needed for much of the technology we take for granted including laptops, tablets, mobile phones, gaming consoles, and automobiles – a sector that seems to be at the root of the current crisis.
Any weekend mechanic knows that even traditional internal combustion cars are heavily reliant on electronics. In fact, electronic parts and components account for 40% of a new, internal combustion vehicle. That’s more than doubled since 2000.
However as it turns out, some manufacturers may have overestimated how soon consumers would be ready for an “all-electric” future. And that meant that they didn’t forecast how much demand there would be for the kind of chips needed to do the mundane, but vital tasks of steering, braking, and even powering windows up and down.
Part of the problem is that U.S. businesses are heavily reliant on countries like China and Taiwan for their semiconductors. In fact, only about 12.5% of semiconductor manufacturing is done in the United States.
Of course, this creates a tremendous opportunity for the companies that manufacture these chips. And it comes at a good time. The semiconductor sector is notoriously cyclical and was coming down from the elevated demand for the 5G buildout.
In this special presentation, we’ll give you a list of seven semiconductor companies that you can invest in to take advantage of this opportunity.
View the "7 Semiconductor Stocks Set to Gain From the Chip Shortage".